310 related articles for article (PubMed ID: 19261849)
1. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation.
Salvesen HB; Carter SL; Mannelqvist M; Dutt A; Getz G; Stefansson IM; Raeder MB; Sos ML; Engelsen IB; Trovik J; Wik E; Greulich H; Bø TH; Jonassen I; Thomas RK; Zander T; Garraway LA; Oyan AM; Sellers WR; Kalland KH; Meyerson M; Akslen LA; Beroukhim R
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4834-9. PubMed ID: 19261849
[TBL] [Abstract][Full Text] [Related]
2.
Holst F; Werner HMJ; Mjøs S; Hoivik EA; Kusonmano K; Wik E; Berg A; Birkeland E; Gibson WJ; Halle MK; Trovik J; Cherniack AD; Kalland KH; Mills GB; Singer CF; Krakstad C; Beroukhim R; Salvesen HB
Clin Cancer Res; 2019 Jan; 25(1):334-345. PubMed ID: 30442683
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway.
Murayama-Hosokawa S; Oda K; Nakagawa S; Ishikawa S; Yamamoto S; Shoji K; Ikeda Y; Uehara Y; Fukayama M; McCormick F; Yano T; Taketani Y; Aburatani H
Oncogene; 2010 Apr; 29(13):1897-908. PubMed ID: 20062086
[TBL] [Abstract][Full Text] [Related]
4. Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma.
Wik E; Ræder MB; Krakstad C; Trovik J; Birkeland E; Hoivik EA; Mjos S; Werner HM; Mannelqvist M; Stefansson IM; Oyan AM; Kalland KH; Akslen LA; Salvesen HB
Clin Cancer Res; 2013 Mar; 19(5):1094-105. PubMed ID: 23319822
[TBL] [Abstract][Full Text] [Related]
5. High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition.
Wik E; Birkeland E; Trovik J; Werner HM; Hoivik EA; Mjos S; Krakstad C; Kusonmano K; Mauland K; Stefansson IM; Holst F; Petersen K; Oyan AM; Simon R; Kalland KH; Ricketts W; Akslen LA; Salvesen HB
Clin Cancer Res; 2013 May; 19(9):2331-41. PubMed ID: 23538402
[TBL] [Abstract][Full Text] [Related]
6. Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations.
Catasus L; D'Angelo E; Pons C; Espinosa I; Prat J
Mod Pathol; 2010 May; 23(5):694-702. PubMed ID: 20173732
[TBL] [Abstract][Full Text] [Related]
7. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.
Cheung LW; Hennessy BT; Li J; Yu S; Myers AP; Djordjevic B; Lu Y; Stemke-Hale K; Dyer MD; Zhang F; Ju Z; Cantley LC; Scherer SE; Liang H; Lu KH; Broaddus RR; Mills GB
Cancer Discov; 2011 Jul; 1(2):170-85. PubMed ID: 21984976
[TBL] [Abstract][Full Text] [Related]
8. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.
Oda K; Stokoe D; Taketani Y; McCormick F
Cancer Res; 2005 Dec; 65(23):10669-73. PubMed ID: 16322209
[TBL] [Abstract][Full Text] [Related]
9. KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.
Birkeland E; Wik E; Mjøs S; Hoivik EA; Trovik J; Werner HM; Kusonmano K; Petersen K; Raeder MB; Holst F; Øyan AM; Kalland KH; Akslen LA; Simon R; Krakstad C; Salvesen HB
Br J Cancer; 2012 Dec; 107(12):1997-2004. PubMed ID: 23099803
[TBL] [Abstract][Full Text] [Related]
10. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.
Berg A; Hoivik EA; Mjøs S; Holst F; Werner HM; Tangen IL; Taylor-Weiner A; Gibson WJ; Kusonmano K; Wik E; Trovik J; Halle MK; Øyan AM; Kalland KH; Cherniack AD; Beroukhim R; Stefansson I; Mills GB; Krakstad C; Salvesen HB
Oncotarget; 2015 Jan; 6(2):1327-39. PubMed ID: 25415225
[TBL] [Abstract][Full Text] [Related]
11. Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma.
Kang S; Seo SS; Chang HJ; Yoo CW; Park SY; Dong SM
Int J Gynecol Cancer; 2008; 18(6):1339-43. PubMed ID: 18221484
[TBL] [Abstract][Full Text] [Related]
12. Activated mutant p110α causes endometrial carcinoma in the setting of biallelic Pten deletion.
Joshi A; Miller C; Baker SJ; Ellenson LH
Am J Pathol; 2015 Apr; 185(4):1104-13. PubMed ID: 25698082
[TBL] [Abstract][Full Text] [Related]
13. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
Oda K; Okada J; Timmerman L; Rodriguez-Viciana P; Stokoe D; Shoji K; Taketani Y; Kuramoto H; Knight ZA; Shokat KM; McCormick F
Cancer Res; 2008 Oct; 68(19):8127-36. PubMed ID: 18829572
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide single nucleotide polymorphism arrays as a diagnostic tool in patients with synchronous endometrial and ovarian cancer.
Ikeda Y; Oda K; Nakagawa S; Murayama-Hosokawa S; Yamamoto S; Ishikawa S; Wang L; Takazawa Y; Maeda D; Wada-Hiraike O; Kawana K; Fukayama M; Aburatani H; Yano T; Kozuma S; Taketani Y
Int J Gynecol Cancer; 2012 Jun; 22(5):725-31. PubMed ID: 22635024
[TBL] [Abstract][Full Text] [Related]
15. Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation.
Karlsson T; Krakstad C; Tangen IL; Hoivik EA; Pollock PM; Salvesen HB; Lewis AE
Oncotarget; 2017 Jan; 8(3):3881-3894. PubMed ID: 28002804
[TBL] [Abstract][Full Text] [Related]
16. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.
Saal LH; Johansson P; Holm K; Gruvberger-Saal SK; She QB; Maurer M; Koujak S; Ferrando AA; Malmström P; Memeo L; Isola J; Bendahl PO; Rosen N; Hibshoosh H; Ringnér M; Borg A; Parsons R
Proc Natl Acad Sci U S A; 2007 May; 104(18):7564-9. PubMed ID: 17452630
[TBL] [Abstract][Full Text] [Related]
17. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
Garcia-Dios DA; Lambrechts D; Coenegrachts L; Vandenput I; Capoen A; Webb PM; Ferguson K; ; Akslen LA; Claes B; Vergote I; Moerman P; Van Robays J; Marcickiewicz J; Salvesen HB; Spurdle AB; Amant F
Gynecol Oncol; 2013 Feb; 128(2):327-34. PubMed ID: 23219661
[TBL] [Abstract][Full Text] [Related]
18. Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma.
Byun DS; Cho K; Ryu BK; Lee MG; Park JI; Chae KS; Kim HJ; Chi SG
Int J Cancer; 2003 Apr; 104(3):318-27. PubMed ID: 12569555
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA alterations in Middle Eastern ovarian cancers.
Abubaker J; Bavi P; Al-Haqawi W; Jehan Z; Munkarah A; Uddin S; Al-Kuraya KS
Mol Cancer; 2009 Jul; 8():51. PubMed ID: 19638206
[TBL] [Abstract][Full Text] [Related]
20. PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer.
Gonzalez-Bosquet J; Bakkum-Gamez JN; Weaver AL; McGree ME; Dowdy SC; Famuyide AO; Kipp BR; Halling KC; Couch FJ; Podratz KC
Gynecol Oncol; 2021 Jul; 162(1):182-189. PubMed ID: 33867147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
